Idogen AB
IDOGEN
Company Profile
Business description
Idogen AB is a Swedish biotech company engaged in developing tolerogenic cell therapies to prevent biological drugs, transplanted or body cells or tissues from being attacked by the patient's immune system. Its product IDO 8, treats patients with severe hemorrhagic disease.
Contact
Medicon Village
Scheelevagen 2
Lund223 81
SWET: +46 462756330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,576.60 | 46.80 | 0.55% |
| CAC 40 | 7,853.47 | 16.68 | 0.21% |
| DAX 40 | 23,695.59 | 168.58 | 0.72% |
| Dow JONES (US) | 42,322.75 | 271.69 | 0.65% |
| FTSE 100 | 8,633.75 | 48.74 | 0.57% |
| HKSE | 23,262.80 | 190.36 | -0.81% |
| NASDAQ | 19,112.32 | 34.49 | -0.18% |
| Nikkei 225 | 37,734.00 | 21.51 | -0.06% |
| NZX 50 Index | 12,791.30 | 89.52 | -0.69% |
| S&P 500 | 5,916.93 | 24.35 | 0.41% |
| S&P/ASX 200 | 8,341.60 | 44.10 | 0.53% |
| SSE Composite Index | 3,363.32 | 17.50 | -0.52% |